FunctionalNanoTher
Financiado
Functional Nanoscale Therapeutics
We will develop new functional nanoscale medicines that engage and co-operate with cellular pathways that were designed to process and extract useful information from endogenous nanostructures, as well as protect the organism from...
We will develop new functional nanoscale medicines that engage and co-operate with cellular pathways that were designed to process and extract useful information from endogenous nanostructures, as well as protect the organism from nanoscale pathogens. We show how functional hybrid nanostructures, part-synthetic and part-cell-derived biomolecular condensate, elicit the full repertoire of cellular processing steps. In particular the enabling of highly efficient escape from endosomes and providing intracellular access to nanostructure embedded biomolecular networks. We show how cellular defences include nanoscale molecular interaction gating mechanisms that grant access on the formation of prescribed molecular assemblies that act as ‘access key codes’. The assembled molecular interactions at these gates may be captured and analysed using time-resolved spatially localized chemical reactions within the cell, and the enabling assemblies analysed in molecular detail. The cell-derived condensate portion of the hybrid particles may be re-engineered to incorporate foreign proteins and RNAs, while retaining overall function, and the new biomolecules can then be delivered to intracellular locations with their function intact. These advances make it possible to understand the connection between nanostructure architecture and function, and thereby open the pathway to recapitulate the functional nanostructures using purely preparative methods. To apply these systems we first propose to use functional nanostructures to deliver specifically optimised mRNA for Covid-19 spike protein into the cell, optimising mRNA metabolism to benefit from endogenous intracellular access. We then propose to engineer and deliver cooperative networks of multiple mRNA, with the prospect of being able to develop functional nanoscale therapies that can counter more extended dysfunctional networks such as those found in the tumour microenvironment.
ver más
Duración del proyecto: 59 meses
Fecha Inicio: 2024-01-01
Fecha Fin: 2028-12-31
Fecha Fin: 2028-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-01-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-ADG:
ERC ADVANCED GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5